Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 333
- Registration Number
- NCT00309608
- Locations
- 🇫🇷
1218.6.3305A Euraxi Pharma, Joue les Tours, France
🇸🇰1218.6.42105 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia
🇸🇰1218.6.42104 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
- Conditions
- Interventions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 746
- Registration Number
- NCT00294723
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Rio Piedras, Puerto Rico
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 547
- Registration Number
- NCT00225277
Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 458
- Registration Number
- NCT00225264
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3118
- Registration Number
- NCT00106340
- Locations
- 🇩🇪
Investigative Centers, Nurnberg, Germany
🇺🇸Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 515
- Registration Number
- NCT00099944
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione
- Conditions
- First Posted Date
- 2002-08-30
- Last Posted Date
- 2008-06-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 170
- Registration Number
- NCT00044447
- Locations
- 🇺🇸
Dallas Diabetes & Endocrine Center, Dallas, Texas, United States
Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
- Conditions
- Interventions
- First Posted Date
- 2002-03-22
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 1791
- Registration Number
- NCT00032487
- Locations
- 🇺🇸
Southern Arizona VA Health Care System, Tucson, Tucson, Arizona, United States
🇺🇸VA Medical Center, Long Beach, Long Beach, California, United States
🇺🇸Edward Hines, Jr. VA Hospital, Hines, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.